Accordingly, CD70 is an enticing target in immuno-oncology (22, 23, 26) and several targeted immunotherapies are currently in clinical development, including the monoclonal antibody cusatuzumab (43, 44), and the allogeneic CAR T-cell therapies CTX130 and ALLO-316, both of which are being investigated in RCC (45, 46). Here, CD70 is linked to renal cell carcinoma.